Lomitapide
JUXTAPID
- Dosage form
- Tablet
- Available strengths
- 5 mg, 10 mg, 20 mg
- Drug class
- Microsomal triglyceride transfer protein (MTP) inhibitor
- Common brand
- JUXTAPID
Clinical overview. Lomitapide is an oral microsomal triglyceride transfer protein (MTP) inhibitor (brand name JUXTAPID) used alongside a strict low-fat diet and other lipid-lowering therapies to reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia. The dose is escalated gradually from 5 mg to a maximum of 60 mg once daily to limit gastrointestinal side effects, and liver enzymes must be monitored regularly because of the risk of elevated transaminases and fat accumulation in the liver. It is contraindicated in pregnancy and in moderate-to-severe liver disease, and interacts significantly with statins, warfarin, and CYP3A4 inhibitors including grapefruit juice.
Indication
Common therapeutic uses
- Lomitapide is used as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia (HoFH).
- Because of its safety profile, treatment should be limited to physicians experienced in diagnosing and treating familial hypercholesterolemia.
- The effect of lomitapide on cardiovascular illness and death has not been established.
Pregnancy
Risk assessment and monitoring considerations
Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.
- Lomitapide is contraindicated during pregnancy because it may cause fetal harm.
- Lomitapide was teratogenic in rats and ferrets at exposures below the human therapeutic dose, and caused embryo-fetal death in rabbits at higher exposures.
- Before starting treatment, pregnancy should be ruled out in women of childbearing potential and effective contraception started; patients on estrogen-based oral contraceptives should be told that diarrhea or vomiting can reduce contraceptive effectiveness.
- Patients who become pregnant while taking lomitapide should stop the drug immediately and contact their healthcare professional.
Breastfeeding
Infant exposure considerations
- It is not known whether lomitapide passes into human breast milk.
- Because lomitapide caused tumours in a 2-year mouse study, a decision should be made whether to discontinue breastfeeding or discontinue lomitapide, taking into account the importance of treatment to the mother.
Geriatrics
Dosing and tolerability considerations
- Clinical studies did not include enough patients 65 years of age and older with HoFH to determine whether they respond differently than younger patients.
- Dosing in elderly patients should be cautious, reflecting the greater likelihood of reduced liver, kidney, or heart function and other concurrent medications.
Pediatrics
Use in children and adolescents
- Safety and effectiveness in patients under 18 years of age have not been established, so Health Canada has not authorized a pediatric indication.
Dosage & Administration
Practical dosing and administration
- The recommended starting dose is 5 mg once daily, taken without food.
- After at least 2 weeks the dose may be increased to 10 mg, then at intervals of at least 4 weeks further increased to 20 mg, 40 mg, and a maximum of 60 mg daily, based on tolerability and LDL-C response.
- Patients should follow a diet supplying less than 20% of calories from fat before and during treatment, since this reduces the frequency and severity of gastrointestinal side effects.
- Daily dietary supplements containing vitamin E and essential fatty acids (linoleic acid, alpha-linolenic acid, EPA, and DHA) are recommended to prevent fat-soluble nutrient deficiency, and should be taken at least 2 hours apart from lomitapide.
- Liver enzymes (ALT and/or AST) should be measured before starting treatment and before each dose increase, then monthly during the first year and every 3 months afterward; dose reduction or discontinuation is required based on the degree of elevation.
- Patients on dialysis for end-stage renal disease should not exceed 40 mg daily; dosing in other forms of renal impairment has not been studied.
- Patients with mild hepatic impairment (Child-Pugh A) should not exceed 40 mg daily; lomitapide is contraindicated in moderate or severe hepatic impairment.
- Capsules should be swallowed whole with a glass of water at least 2 hours after the evening meal, and never opened, crushed, dissolved, or chewed.
- If a dose is missed, take the normal dose the next day at the usual time; contact the healthcare provider before restarting if treatment is interrupted for more than a week.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no specific antidote for lomitapide overdose.
- Overdose should be managed with symptomatic treatment and general supportive care.
- Liver function tests should be monitored after a suspected overdose.
- Because lomitapide is highly bound to blood proteins, hemodialysis is not expected to remove it from the blood.
Common side effects
Frequently reported tolerability concerns
- Diarrhea is very common.
- Nausea is very common.
- Indigestion (dyspepsia) is common.
- Vomiting is common.
- Abdominal pain is common.
- Abdominal bloating (distension) may occur.
- Constipation may occur.
- Gas (flatulence) may occur.
- Heartburn (gastroesophageal reflux) may occur.
- An urgent need to have a bowel movement may occur.
- Weight loss may occur.
- Fatigue may occur.
- Headache may occur.
- Dizziness may occur.
- Back pain may occur.
- Sore throat (pharyngolaryngeal pain) may occur.
- Nasal congestion may occur.
- Flu-like illness may occur.
- Cold-like symptoms (nasopharyngitis) may occur.
- Fever may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Elevated liver enzymes (ALT and/or AST) are common and usually reversible, but require dose adjustment or discontinuation depending on the degree of elevation.
- Hepatic steatosis (fat accumulation in the liver) occurs in most treated patients, and its long-term consequences, including possible progression to steatohepatitis, fibrosis, or cirrhosis, are unknown.
- Severe diarrhea and dehydration can occur, increasing the risk of low blood pressure and fainting, particularly in older adults or those taking diuretics.
- Chest pain has been reported.
- Angina pectoris (chest pain from reduced blood flow to the heart) has been reported.
- Heart palpitations have been reported.
- A case of myocardial infarction (heart attack) has been reported.
- Hypersensitivity reactions have been reported.
- Gastrointestinal bleeding, including vomiting blood or blood in the stool, has been reported.
- Hair loss (alopecia) has been reported after treatment.
- Seek urgent medical attention for yellowing of the skin or eyes, dark urine, severe abdominal pain, unusual fatigue, chest pain, or signs of severe dehydration.
Use with caution
Situations requiring closer assessment
- Use with caution in patients who consume alcohol, since it can worsen liver injury, including hepatic steatosis; limit to no more than one drink daily.
- Use with caution when combining with other drugs known to cause liver injury, such as isotretinoin, amiodarone, high-dose acetaminophen, methotrexate, tetracyclines, and tamoxifen, and consider more frequent liver monitoring.
- Use with caution in geriatric patients or those taking diuretics, given the increased risk of dehydration and low blood pressure from severe diarrhea.
- Use with caution when combining with statins, since lomitapide increases statin blood levels and the risk of muscle toxicity, particularly with simvastatin.
- Use with caution in patients taking warfarin, since lomitapide increases warfarin levels and INR should be monitored more frequently after starting or adjusting lomitapide.
- Avoid grapefruit juice completely during treatment, since it inhibits the enzyme that breaks down lomitapide.
- Baseline imaging assessment of hepatic fibrosis, along with periodic laboratory markers of liver inflammation and fibrosis, should be carried out given the risk of hepatic fat accumulation.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with moderate or severe hepatic impairment, including those with unexplained persistent abnormal liver function tests.
- Contraindicated in patients with significant chronic bowel disease, such as inflammatory bowel disease or malabsorption.
- Contraindicated with concomitant use of more than 20 mg daily simvastatin (40 mg is allowed only if the patient has previously tolerated 80 mg daily for at least a year without muscle toxicity).
- Contraindicated with concomitant use of strong or moderate CYP3A4 inhibitors.
- Contraindicated during pregnancy.
- Contraindicated in patients with rare hereditary problems of galactose intolerance, Lapp-lactase deficiency, or glucose-galactose malabsorption.
- Contraindicated in patients with known hypersensitivity to lomitapide or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Drug interactions
Clinically relevant combinations
- Strong and moderate CYP3A4 inhibitors, such as ketoconazole, clarithromycin, and itraconazole, are contraindicated, since they can increase lomitapide levels dramatically and raise the risk of toxicity.
- Weak CYP3A4 inhibitors, including atorvastatin, oral contraceptives, amiodarone, and cyclosporine among others, increase lomitapide exposure; doses should be separated by 12 hours or the lomitapide dose reduced.
- Lomitapide increases simvastatin exposure substantially, requiring a lower simvastatin dose to reduce the risk of muscle toxicity, including rhabdomyolysis.
- Lomitapide increases warfarin levels and INR, so more frequent INR monitoring is needed after starting lomitapide or changing its dose.
- Lomitapide is a P-glycoprotein inhibitor and may increase absorption of P-gp substrates such as digoxin, dabigatran, and colchicine, so dose reduction of these drugs should be considered.
- Bile acid sequestrants can interfere with lomitapide absorption, so dosing should be separated by at least 4 hours.
- Lomitapide has only a minor effect on atorvastatin, rosuvastatin, fenofibrate, ezetimibe, extended-release niacin, ethinyl estradiol, or norgestimate levels, so no dose adjustment is typically needed for these.
Food interactions
Meal-related administration
- Lomitapide should be taken without food, since taking it with food increases drug exposure and may worsen gastrointestinal side effects.
- Grapefruit juice must be avoided completely during treatment, since it moderately inhibits the enzyme responsible for breaking down lomitapide.
Time of administration
Practical scheduling
- Take lomitapide once daily in the evening with a glass of water, at least 2 hours after the evening meal.
Storage
Product handling
- Store at 15°C to 30°C, with the container tightly closed and protected from moisture.
Patient take-away
Key counselling points for a quick closing summary
- Lomitapide (JUXTAPID) is an add-on treatment for homozygous familial hypercholesterolemia, taken once daily without food alongside a strict low-fat diet, other cholesterol medications, and daily vitamin and fatty-acid supplements.
- The dose is increased gradually over several months to reduce stomach upset, and liver blood tests are checked regularly throughout treatment.
- Diarrhea, nausea, and stomach discomfort are common, especially early in treatment or with higher-fat meals; avoid grapefruit juice and limit alcohol.
- Tell your healthcare professional right away if you become pregnant, notice yellowing of the skin or eyes, or develop severe abdominal pain or unusual fatigue.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.